

Immune Check Point Inhibitor-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/IDB966DF1D3EN.html>

Date: December 2017

Pages: 150

Price: US\$ 3,480.00 (Single User License)

ID: IDB966DF1D3EN

Abstracts

Report Summary

Immune Check Point Inhibitor-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Immune Check Point Inhibitor industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Immune Check Point Inhibitor 2013-2017, and development forecast 2018-2023

Main market players of Immune Check Point Inhibitor in EMEA, with company and product introduction, position in the Immune Check Point Inhibitor market

Market status and development trend of Immune Check Point Inhibitor by types and applications

Cost and profit status of Immune Check Point Inhibitor, and marketing status

Market growth drivers and challenges

The report segments the EMEA Immune Check Point Inhibitor market as:

EMEA Immune Check Point Inhibitor Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Immune Check Point Inhibitor Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

CTLA 4
PD 1
Others

EMEA Immune Check Point Inhibitor Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Medical Care
Experiment
Others

EMEA Immune Check Point Inhibitor Market: Players Segment Analysis (Company and
Product introduction, Immune Check Point Inhibitor Sales Volume, Revenue, Price and
Gross Margin):

Advaxis
Agenus
Amgen
Bristol Myers Squibb
Faron Pharmaceuticals
Genentech
Genocea
Incyte Corporation
Innate Pharma
Kite Pharma
MacroGenics
Merck
NewLink Genetics Corp
Sorrento Therapeutics
TG Therapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF IMMUNE CHECK POINT INHIBITOR

- 1.1 Definition of Immune Check Point Inhibitor in This Report
- 1.2 Commercial Types of Immune Check Point Inhibitor
 - 1.2.1 CTLA
 - 1.2.2 PD
 - 1.2.3 Others
- 1.3 Downstream Application of Immune Check Point Inhibitor
 - 1.3.1 Medical Care
 - 1.3.2 Experiment
 - 1.3.3 Others
- 1.4 Development History of Immune Check Point Inhibitor
- 1.5 Market Status and Trend of Immune Check Point Inhibitor 2013-2023
 - 1.5.1 EMEA Immune Check Point Inhibitor Market Status and Trend 2013-2023
 - 1.5.2 Regional Immune Check Point Inhibitor Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Immune Check Point Inhibitor in EMEA 2013-2017
- 2.2 Consumption Market of Immune Check Point Inhibitor in EMEA by Regions
 - 2.2.1 Consumption Volume of Immune Check Point Inhibitor in EMEA by Regions
 - 2.2.2 Revenue of Immune Check Point Inhibitor in EMEA by Regions
- 2.3 Market Analysis of Immune Check Point Inhibitor in EMEA by Regions
 - 2.3.1 Market Analysis of Immune Check Point Inhibitor in Europe 2013-2017
 - 2.3.2 Market Analysis of Immune Check Point Inhibitor in Middle East 2013-2017
 - 2.3.3 Market Analysis of Immune Check Point Inhibitor in Africa 2013-2017
- 2.4 Market Development Forecast of Immune Check Point Inhibitor in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Immune Check Point Inhibitor in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Immune Check Point Inhibitor by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Immune Check Point Inhibitor in EMEA by Types
 - 3.1.2 Revenue of Immune Check Point Inhibitor in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Immune Check Point Inhibitor in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Immune Check Point Inhibitor in EMEA by Downstream Industry

4.2 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Major Countries

4.2.1 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Europe

4.2.2 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Middle East

4.2.3 Demand Volume of Immune Check Point Inhibitor by Downstream Industry in Africa

4.3 Market Forecast of Immune Check Point Inhibitor in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

5.1 EMEA Economy Situation and Trend Overview

5.2 Immune Check Point Inhibitor Downstream Industry Situation and Trend Overview

CHAPTER 6 IMMUNE CHECK POINT INHIBITOR MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Immune Check Point Inhibitor in EMEA by Major Players

6.2 Revenue of Immune Check Point Inhibitor in EMEA by Major Players

6.3 Basic Information of Immune Check Point Inhibitor by Major Players

6.3.1 Headquarters Location and Established Time of Immune Check Point Inhibitor Major Players

6.3.2 Employees and Revenue Level of Immune Check Point Inhibitor Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 IMMUNE CHECK POINT INHIBITOR MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Advaxis

7.1.1 Company profile

7.1.2 Representative Immune Check Point Inhibitor Product

7.1.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Advaxis

7.2 Agenus

7.2.1 Company profile

7.2.2 Representative Immune Check Point Inhibitor Product

7.2.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Agenus

7.3 Amgen

7.3.1 Company profile

7.3.2 Representative Immune Check Point Inhibitor Product

7.3.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Amgen

7.4 Bristol Myers Squibb

7.4.1 Company profile

7.4.2 Representative Immune Check Point Inhibitor Product

7.4.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Bristol Myers Squibb

7.5 Faron Pharmaceuticals

7.5.1 Company profile

7.5.2 Representative Immune Check Point Inhibitor Product

7.5.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Faron Pharmaceuticals

7.6 Genentech

7.6.1 Company profile

7.6.2 Representative Immune Check Point Inhibitor Product

7.6.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Genentech

7.7 Genocea

7.7.1 Company profile

7.7.2 Representative Immune Check Point Inhibitor Product

7.7.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Genocea

7.8 Incyte Corporation

7.8.1 Company profile

7.8.2 Representative Immune Check Point Inhibitor Product

7.8.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Incyte Corporation

7.9 Innate Pharma

7.9.1 Company profile

7.9.2 Representative Immune Check Point Inhibitor Product

7.9.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Innate Pharma

7.10 Kite Pharma

7.10.1 Company profile

7.10.2 Representative Immune Check Point Inhibitor Product

7.10.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Kite Pharma

7.11 MacroGenics

7.11.1 Company profile

7.11.2 Representative Immune Check Point Inhibitor Product

7.11.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of MacroGenics

7.12 Merck

7.12.1 Company profile

7.12.2 Representative Immune Check Point Inhibitor Product

7.12.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Merck

7.13 NewLink Genetics Corp

7.13.1 Company profile

7.13.2 Representative Immune Check Point Inhibitor Product

7.13.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of NewLink Genetics Corp

7.14 Sorrento Therapeutics

7.14.1 Company profile

7.14.2 Representative Immune Check Point Inhibitor Product

7.14.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of Sorrento Therapeutics

7.15 TG Therapeutics

7.15.1 Company profile

7.15.2 Representative Immune Check Point Inhibitor Product

7.15.3 Immune Check Point Inhibitor Sales, Revenue, Price and Gross Margin of TG

Therapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

- 8.1 Industry Chain of Immune Check Point Inhibitor
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

- 9.1 Cost Structure Analysis of Immune Check Point Inhibitor
- 9.2 Raw Materials Cost Analysis of Immune Check Point Inhibitor
- 9.3 Labor Cost Analysis of Immune Check Point Inhibitor
- 9.4 Manufacturing Expenses Analysis of Immune Check Point Inhibitor

CHAPTER 10 MARKETING STATUS ANALYSIS OF IMMUNE CHECK POINT INHIBITOR

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Immune Check Point Inhibitor-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/IDB966DF1D3EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IDB966DF1D3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970